Debanjana Chatterjee
Stock Analyst at Jones Trading
(2.97)
# 1,401
Out of 4,901 analysts
10
Total ratings
77.78%
Success rate
24.12%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Debanjana Chatterjee
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TBPH Theravance Biopharma | Initiates: Buy | $24 | $11.65 | +106.01% | 1 | Jun 17, 2025 | |
| SGMT Sagimet Biosciences | Maintains: Buy | $15 → $27 | $9.56 | +182.43% | 2 | Jun 6, 2025 | |
| TVRD Tvardi Therapeutics | Initiates: Buy | $39 | $22.74 | +71.50% | 1 | Apr 28, 2025 | |
| KALV KalVista Pharmaceuticals | Maintains: Buy | $30 | $15.79 | +89.99% | 2 | Mar 26, 2025 | |
| CTNM Contineum Therapeutics | Initiates: Buy | $23 | $3.81 | +504.47% | 1 | Mar 13, 2025 | |
| SYRE Spyre Therapeutics | Initiates: Hold | n/a | $16.20 | - | 1 | Dec 11, 2024 | |
| PHVS Pharvaris | Initiates: Buy | $46 | $23.00 | +100.00% | 1 | Sep 19, 2024 | |
| NTLA Intellia Therapeutics | Initiates: Buy | $41 | $11.96 | +242.81% | 1 | Sep 17, 2024 |
Theravance Biopharma
Jun 17, 2025
Initiates: Buy
Price Target: $24
Current: $11.65
Upside: +106.01%
Sagimet Biosciences
Jun 6, 2025
Maintains: Buy
Price Target: $15 → $27
Current: $9.56
Upside: +182.43%
Tvardi Therapeutics
Apr 28, 2025
Initiates: Buy
Price Target: $39
Current: $22.74
Upside: +71.50%
KalVista Pharmaceuticals
Mar 26, 2025
Maintains: Buy
Price Target: $30
Current: $15.79
Upside: +89.99%
Contineum Therapeutics
Mar 13, 2025
Initiates: Buy
Price Target: $23
Current: $3.81
Upside: +504.47%
Spyre Therapeutics
Dec 11, 2024
Initiates: Hold
Price Target: n/a
Current: $16.20
Upside: -
Pharvaris
Sep 19, 2024
Initiates: Buy
Price Target: $46
Current: $23.00
Upside: +100.00%
Intellia Therapeutics
Sep 17, 2024
Initiates: Buy
Price Target: $41
Current: $11.96
Upside: +242.81%